These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30318880)

  • 1. Effects of progestogens in women with preterm premature rupture of membranes.
    Di Sarno R; Raffone A; Saccone G
    Minerva Ginecol; 2019 Apr; 71(2):121-124. PubMed ID: 30318880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
    Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
    Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Double-Blind, Randomized, Placebo-Controlled Trial of 17 Alpha-hydroxyprogesterone Caproate in the Management of Preterm Premature Rupture of Membranes.
    Langen ES; Sit A; Sherwin K; Lyell DJ; Blumenfeld YJ; El-Sayed YY
    Am J Perinatol; 2018 Jul; 35(8):779-784. PubMed ID: 29298456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.
    EPPPIC Group
    Lancet; 2021 Mar; 397(10280):1183-1194. PubMed ID: 33773630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
    Oler E; Eke AC; Hesson A
    Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
    Suhag A; Saccone G; Berghella V
    Am J Obstet Gynecol; 2015 Oct; 213(4):479-87. PubMed ID: 25797233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
    Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
    Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
    Alizadeh F; Mahmoudinia M; Mirteimoori M; Pourali L; Niroumand S
    BMC Pregnancy Childbirth; 2022 Mar; 22(1):167. PubMed ID: 35232423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
    Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
    Facchinetti F; Vergani P; Di Tommaso M; Marozio L; Acaia B; Vicini R; Pignatti L; Locatelli A; Spitaleri M; Benedetto C; Zaina B; DʼAmico R
    Obstet Gynecol; 2017 Jul; 130(1):64-70. PubMed ID: 28594783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROLONG Clinical Study Protocol: Hydroxyprogesterone Caproate to Reduce Recurrent Preterm Birth.
    Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck T; Miller HS; Das AF; Birch R; Jozwiakowski MJ
    Am J Perinatol; 2018 Oct; 35(12):1228-1234. PubMed ID: 29702708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
    Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
    J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestogens and prevention of preterm birth in women at risk.
    Prescrire Int; 2016 Jul; 25(173):185-188. PubMed ID: 30730653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB; McIntire DD; Leveno KJ
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
    Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.